| Alicia Moncerate Villeneuve, CRNA | |
|
601 E Rollins St, Orlando, FL 32803-1248 | |
| (407) 667-0444 | |
| Not Available |
| Full Name | Alicia Moncerate Villeneuve |
|---|---|
| Gender | Female |
| Speciality | Nurse Anesthetist, Certified Registered |
| Location | 601 E Rollins St, Orlando, Florida |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1043927510 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367500000X | Nurse Anesthetist, Certified Registered | APRN11029606 (Florida) | Primary |
| Entity Name | Us Anesthesia Partners Of Florida Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1518910520 PECOS PAC ID: 0345143152 Enrollment ID: O20040129000594 |
News Archive
Portola Pharmaceuticals, Inc. today announced that it has initiated its first in human Phase 1 trial in healthy volunteers of PRT062607, a novel, oral Syk-specific kinase inhibitor in development to treat chronic inflammatory diseases, including rheumatoid arthritis (RA), and certain cancers, including non-Hodgkin's lymphoma and chronic lymphocytic leukemia. In preclinical in vivo models of RA, PRT062607 was shown to reduce inflammation in a dose-dependent manner.
As COVID-19 continues to rage across the U.S., researchers are digging deeper into how the virus wreaks havoc on the body, especially for those with a pre-existing chronic illness.
In the growing global battle against substandard and counterfeit medicines, the Promoting the Quality of Medicines program has launched a new, public database of medicines collected and analyzed in collaboration with stakeholders from countries in Africa, South America and Southeast Asia.
Working together to reduce the occurrence of pressure ulcers in patients throughout various care settings, members of the New Jersey Hospital Association's Pressure Ulcer Collaborative have reported a 70 percent reduction in the incidence of new pressure ulcers after nearly two years of applying shared best practices and preventive techniques.
Attaching an antimicrobial drug, which is activated by light, to a peptide that binds to bacteria and stops them making toxins, produced a "magic bullet" that was highly effective at killing the superbug, methicillin-resistant Staphylococcus aureus (MRSA).
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Alicia Moncerate Villeneuve, CRNA 851 Trafalgar Ct Ste 200e, Maitland, FL 32751-7420 Ph: (407) 667-0444 | Alicia Moncerate Villeneuve, CRNA 601 E Rollins St, Orlando, FL 32803-1248 Ph: (407) 667-0444 |
News Archive
Portola Pharmaceuticals, Inc. today announced that it has initiated its first in human Phase 1 trial in healthy volunteers of PRT062607, a novel, oral Syk-specific kinase inhibitor in development to treat chronic inflammatory diseases, including rheumatoid arthritis (RA), and certain cancers, including non-Hodgkin's lymphoma and chronic lymphocytic leukemia. In preclinical in vivo models of RA, PRT062607 was shown to reduce inflammation in a dose-dependent manner.
As COVID-19 continues to rage across the U.S., researchers are digging deeper into how the virus wreaks havoc on the body, especially for those with a pre-existing chronic illness.
In the growing global battle against substandard and counterfeit medicines, the Promoting the Quality of Medicines program has launched a new, public database of medicines collected and analyzed in collaboration with stakeholders from countries in Africa, South America and Southeast Asia.
Working together to reduce the occurrence of pressure ulcers in patients throughout various care settings, members of the New Jersey Hospital Association's Pressure Ulcer Collaborative have reported a 70 percent reduction in the incidence of new pressure ulcers after nearly two years of applying shared best practices and preventive techniques.
Attaching an antimicrobial drug, which is activated by light, to a peptide that binds to bacteria and stops them making toxins, produced a "magic bullet" that was highly effective at killing the superbug, methicillin-resistant Staphylococcus aureus (MRSA).
› Verified 6 days ago
Danielle Larson, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 601 E Rollins St, Orlando, FL 32803 Phone: 407-667-0444 Fax: 407-667-4338 | |
Mary Amber Davis, RN Nurse Anesthetist - CR Medicare: Medicare Enrolled Practice Location: 27 Wintergreen Way, Orlando, FL 32825 Phone: 386-216-8994 | |
Darmela Shannon Thornton, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 601 E Rollins St, Orlando, FL 32803 Phone: 407-303-5600 | |
Stacey L. Bettes, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 225 E Robinson St, Suite 130, Orlando, FL 32801 Phone: 407-581-9180 Fax: 865-560-7066 | |
Amanda Gabriele Hermida, RN Nurse Anesthetist - CR Medicare: Medicare Enrolled Practice Location: 52 W Underwood St, Orlando, FL 32806 Phone: 321-841-5111 | |
Mr. Said Ricardo Acosta, CRNA Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 13535 Nemours Pkwy, Orlando, FL 32827 Phone: 407-567-4000 Fax: 407-650-7124 | |
William R Kogl, CRNA Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 400 N Mills Ave, Orlando, FL 32803 Phone: 407-872-2244 Fax: 407-926-9173 |